|
1
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shaib YH, Davila JA, McGlynn K and
El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in
the United States: A true increase? J Hepatol. 40:472–477. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mosconi S, Beretta GD, Labianca R, Zampino
MG, Gatta G and Heinemann V: Cholangiocarcinoma. Crit Rev Oncol
Hematol. 69:259–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shin HR, Oh JK, Masuyer E, Curado MP,
Bouvard V, Fang YY, Wiangnon S, Sripa B and Hong ST: Epidemiology
of cholangiocarcinoma: An update focusing on risk factors. Cancer
Sci. 101:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pattanathien P, Khuntikeo N, Promthet S
and Kamsa-Ard S: Survival rate of extrahepatic cholangiocarcinoma
patients after surgical treatment in Thailand. Asian Pac J Cancer
Prev. 14:321–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Donato F, Gelatti U, Tagger A, Favret M,
Ribero ML, Callea F, Martelli C, Savio A, Trevisi P and Nardi G:
Intrahepatic cholangiocarcinoma and hepatitis C and B virus
infection, alcohol intake and hepatolithiasis: A case-control study
in Italy. Cancer Causes Control. 12:959–964. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Dell MR, Huang JL, Whitney-Miller CL,
Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H,
Bardeesy N and Hezel AF: Kras (G12D) and p53 mutation cause primary
intrahepatic cholangiocarcinoma. Cancer Res. 72:1557–1567. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sripa B, Kaewkes S, Sithithaworn P,
Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana
S, Thinkamrop B, et al: Liver fluke induces cholangiocarcinoma.
PLoS Med. 4:e2012007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanapa P and Watanapa WB: Liver
fluke-associated cholangiocarcinoma. Br J Surg. 89:962–970. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Welzel TM, Graubard BI, El-Serag HB, Shaib
YH, Hsing AW, Davila JA and McGlynn KA: Risk factors for
intrahepatic and extrahepatic cholangiocarcinoma in the United
States: A population-based case-control study. Clin Gastroenterol
Hepatol. 5:1221–1228. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shaib YH, El-Serag HB, Nooka AK, Thomas M,
Brown TD, Patt YZ and Hassan MM: Risk factors for intrahepatic and
extrahepatic cholangiocarcinoma: A hospital-based case-control
study. Am J Gastroenterol. 102:1016–1021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M,
Burke EC, BS J Bodniewicz, BA M Youssef, Klimstra D and Blumgart
LH: Staging, resectability, and outcome in 225 patients with hilar
cholangiocarcinoma. Ann Surg. 234:507–517; discussion 517–519.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clary B, Jarnigan W, Pitt H, Gores G,
Busuttil R and Pappas T: Hilar cholangiocarcinoma. J Gastrointest
Surg. 8:298–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sudan D, DeRoover A, Chinnakotla S, Fox I,
Shaw B Jr, McCashland T, Sorrell M, Tempero M and Langnas A:
Radiochemotherapy and transplantation allow long-term survival for
nonresectable hilar cholangiocarcinoma. Am J Transplant. 2:774–779.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horgan AM, Amir E, Walter T and Knox JJ:
Adjuvant therapy in the treatment of biliary tract cancer: A
systematic review and meta-analysis. J Clin Oncol. 30:1934–1940.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Monson JR, Donohue JH, Gunderson LL,
Nagorney DM, Bender CE and Wieand HS: Intraoperative radiotherapy
for unresectable cholangiocarcinoma-the Mayo Clinic experience.
Surg Oncol. 1:283–290. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kopek N, Holt MI, Hansen AT and Hoyer M:
Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
Radiother Oncol. 94:47–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moureau-Zabotto L, Turrini O, Resbeut M,
Raoul JL, Giovannini M, Poizat F, Piana G, Delpero JR and Bertucci
F: Impact of radiotherapy in the management of locally advanced
extrahepatic cholangiocarcinoma. BMC Cancer. 13:5682013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shinohara ET, Mitra N, Guo M and Metz JM:
Radiation therapy is associated with improved survival in the
adjuvant and definitive treatment of intrahepatic
cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 72:1495–1501.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pitt HA, Nakeeb A, Abrams RA, Coleman J,
Piantadosi S, Yeo CJ, Lillemore KD and Cameron JL: Perihilar
cholangiocarcinoma. Postoperative radiotherapy does not improve
survival. Ann Surg. 221:788–797; discussion 797–798. 1995.
|
|
24
|
Shinohara ET, Mitra N, Guo M and Metz JM:
Radiotherapy is associated with improved survival in adjuvant and
palliative treatment of extrahepatic cholangiocarcinomas. Int J
Radiat Oncol Biol Phys. 74:1191–1198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Todoroki T, Ohara K, Kawamoto T, Koike N,
Yoshida S, Kashiwagi H, Otsuka M and Fukao K: Benefits of adjuvant
radiotherapy after radical resection of locally advanced main
hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 46:581–587.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sagawa N, Kondo S, Morikawa T, Okushiba S
and Katoh H: Effectiveness of radiation therapy after surgery for
hilar cholangiocarcinoma. Surg Today. 35:548–552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen MF: Peripheral cholangiocarcinoma
(cholangiocellular carcinoma): Clinical features, diagnosis and
treatment. J Gastroenterol Hepatol. 14:1144–1149. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Su CH, Tsay SH, Wu CC, Shyr YM, King KL,
Lee CH, Lui WY, Liu TJ and P'eng FK: Factors influencing
postoperative morbidity, mortality and survival after resection for
hilar cholangiocarcinoma. Ann Surg. 223:384–394. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Becker NS, Rodriguez JA, Barshes NR,
O'Mahony CA, Goss JA and Aloia TA: Outcomes analysis for 280
patients with cholangiocarcinoma treated with liver transplantation
over an 18-year period. J Gastrointest Surg. 12:117–122. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salgia RJ, Singal AG, Fu S, Pelletier S
and Marrero JA: Improved post-transplant survival in the United
States for patients with cholangiocarcinoma after 2000. Dig Dis
Sci. 59:1048–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thuluvath PJ, Rai R, Venbrux AC and Yeo
CJ: Cholangiocarcinoma: A review. Gastroenterologist. 5:306–315.
1997.PubMed/NCBI
|
|
32
|
Nakeeb A, Pitt HA, Sohn TA, Coleman J,
Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ and Cameron
JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar and
distal tumors. Ann Surg. 224:463–473; discussion 473–465. 1996.
|
|
33
|
Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX,
Ye SL, Sun HC, Wang BL, Li D, Wang JH, et al: Consideration of the
role of radiotherapy for unresectable intrahepatic
cholangiocarcinoma: A retrospective analysis of 75 patients. Cancer
J. 12:113–122. 2006.PubMed/NCBI
|
|
34
|
Ben-David MA, Griffith KA, Abu-Isa E,
Lawrence TS, Knol J, Zalupski M and Ben-Josef E: External-beam
radiotherapy for localized extrahepatic cholangiocarcinoma. Int J
Radiat Oncol Biol Phys. 66:772–779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen YX, Zeng ZC, Tang ZY, Fan J, Zhou J,
Jiang W, Zeng MS and Tan YS: Determining the role of external beam
radiotherapy in unresectable intrahepatic cholangiocarcinoma: A
retrospective analysis of 84 patients. BMC Cancer. 10:4922010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rea DJ, Heimbach JK, Rosen CB, Haddock MG,
Alberts SR, Kremers WK, Gores GJ and Nagorney DM: Liver
transplantation with neoadjuvant chemoradiation is more effective
than resection for hilar cholangiocarcinoma. Ann Surg. 242:451–458;
discussion 458–461. 2005.PubMed/NCBI
|
|
37
|
Patel T: Cholangiocarcinoma. Nat Clin
Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barney BM, Olivier KR, Miller RC and
Haddock MG: Clinical outcomes and toxicity using stereotactic body
radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol.
7:672012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Polistina FA, Guglielmi R, Baiocchi C,
Francescon P, Scalchi P, Febbraro A, Costantin G and Ambrosino G:
Chemoradiation treatment with gemcitabine plus stereotactic body
radiotherapy for unresectable, non-metastatic, locally advanced
hilar cholangiocarcinoma. Results of a five year experience.
Radiother Oncol. 99:120–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin G, Toh CH, Wu RC, Ko SF, Ng SH, Chou
WC and Tseng JH: Combined hepatocellular cholangiocarcinoma:
prognostic factors investigated by computed tomography/magnetic
resonance imaging. Int J Clin Pract. 62:1199–1205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Maccioni F, Martinelli M, Al Ansari N,
Kagarmanova A, De Marco V, Zippi M and Marini M: Magnetic resonance
cholangiography: past, present and future: A review. Eur Rev Med
Pharmacol Sci. 14:721–725. 2010.PubMed/NCBI
|
|
42
|
Breitenstein S, Apestegui C and Clavien
PA: Positron emission tomography (PET) for cholangiocarcinoma. HPB
(Oxford). 10:120–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Al-Adra DP, Gill RS, Axford SJ, Shi X,
Kneteman N and Liau SS: Treatment of unresectable intrahepatic
cholangiocarcinoma with yttrium-90 radioembolization: A systematic
review and pooled analysis. Eur J Surg Oncol. 41:120–127. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mouli S, Memon K, Baker T, Benson AB,
Mulcahy MF, Gupta R, Ryu RK, Salem R and Lewandowski RJ: Yttrium-90
radioembolization for intrahepatic cholangiocarcinoma: safety,
response and survival analysis. J Vasc Interv Radiol. 24:1227–1234.
2013. View Article : Google Scholar : PubMed/NCBI
|
